Neural Respiratory Drive Combined With Pro-Brain Natriuretic Peptide (Pro-BNP) as Predictor of Deterioration After Lung Transplantation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07525440

Enrollment

Registered

2026-04-13

Start date

2016-01-01

Completion date

2026-02-01

Last updated

2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Transplantation

Brief summary

Lung transplantation has become a promising therapeutic option for various end-stage lung diseases. However, many factors such as infection, graft rejection, airway complications would cause deterioration and shorten the survival time. It is important to detect the deterioration early and receive treatment timely, which may enhance survival. We hypothesis the decreased neural respiratory drive(NRD) would be increased in the deterioration due to the aggravation of lung. Furthermore, pro-Brain Natriuretic Peptide(pro-BNP) has been reported to be associated with greater mortality after lung transplantation.For this reason, we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration. 80 patients were recruited.They were end-stage lung disease patients admitted to hospital for lung transplantation. The NRD and pro-BNP were monitored before and after lung transplantation.we investigated the NRD and pro-BNP before and after lung transplantation and during deterioration.

Interventions

OTHERNo Intervention: Observational Cohort

no intervention

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 85 Years

Healthy volunteers

Inclusion criteria

The patients with end-stage lung diseases referral to lung transplantation,Including chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasia

Exclusion criteria

(1) Malignancy （2）Severe cardiovascular diseases （3）Neuromuscular and chest wall deformity (4) Cardiovascular instability (hypotension, arrhythmias, myocardial infarction) (5) Change in mental status; uncooperative patients （6）Renal failure and severe blood electrolyte disturbances

Design outcomes

Primary

Measure	Time frame	Description
deterioration	6 years	deterioration rate

Countries

China

Contacts

PRINCIPAL_INVESTIGATORjianheng zhang, MD

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026